T1602

Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.

MCI826 is a potent and selective antagonist of P-glycoprotein (P-gp) and peptide leukotrienes (p-LTs), showing anti-asthmatic activity in a guinea pig model of advanced asthma.

MB05032 is a potent fructose-,-bisphosphatase inhibitor that inhibits gluconeogenesis and reduces d-lactate-triggered ETosis.

MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).

Arhalofenate (JNJ 39659100) is a selective partial agonist of peroxisome proliferator-activated receptor PPARγ. It is used for the treatment of type 2 diabetes.

MC 976 is a derivative of Vitamin D3.

(24R)-MC 976, a derivative of Vitamin D3, is a synthetic chemical compound that mimics the biological effects of the natural vitamin.

(24S)-MC 976, a derivative of Vitamin D3, is described as [(1R,3aR,7aR)-1-[(2S)-6,7-dihydroxy-6-methylheptan-2-yl]-3a-(2-hydroxyethyl)-7a-methyl-octahydro-1H-inden-4-yl](2E)-3-(4-methylphenyl)prop-2-enoate.

MC-GGFG-DX8951 (MC-GGFG-Exatecan) is an antibody-coupled drug (ADC) drug-linker conjugate (DLC) consisting of DX8951, a potent DNA topoisomerase I inhibitor, the linker MC, and the cleavable peptide chain GGFG, and has antitumor potential.

MC-Val-Ala-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala[1].

Mcl1-IN-1 is a myeloid cell factor 1 inhibitor (IC50=2.4 µM).

IMB-XH1 (Mcl1-IN-2) is a myeloid cell factor 1 (Mcl-1) inhibitor.

Mcl1-IN-3 is an Mcl1 inhibitor. It has an IC50 and Ki of 0.67 and 0.13 μM, respectively.

Valproic acid-D14 sodium is the deuterated form of Valproic acid (sodium). Valproic acid sodium (T1602) salt (Sodium Valproate) acts as an HDAC inhibitor, with an IC50 range of 0.5-2 mM, and inhibits the activity of HDAC1 (IC50, 400 μM) while also promoting the degradation of HDAC2. It activates the Notch1 signaling pathway and suppresses the proliferation of small cell lung cancer (SCLC) cells. Additionally, Valproic acid sodium (T1602) salt is applicable in research related to epilepsy, bipolar disorder, and migraines.